Sherwyn L Schwartz

Summary

Affiliation: Diabetes and Glandular Disease Research Associates
Country: USA

Publications

  1. ncbi request reprint A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus
    Sherwyn Schwartz
    Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
    Clin Ther 28:1649-57. 2006
  2. pmc Correct use of a new reusable insulin injection pen by patients with diabetes: a design validation study
    Sherwyn Schwartz
    Diabetes and Glandular Disease Research Associates, San Antonio, Texas 78229, USA
    J Diabetes Sci Technol 4:1229-35. 2010
  3. doi request reprint Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial
    Sherwyn Schwartz
    Cetero Research, San Antonio, TX 78229, USA
    Curr Med Res Opin 27:151-62. 2011
  4. doi request reprint Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Clinic, 5107 Medical Drive, San Antonio, TX 78229, USA
    Ann Med 44:157-69. 2012
  5. ncbi request reprint A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus
    Sherwyn Schwartz
    Diabetes and Glandular Disease Research Associates, 5107 Medical Drive, San Antonio, TX 78229, USA
    Clin Ther 26:1663-78. 2004
  6. doi request reprint Validation of the SoloSTAR insulin pen
    Sherwyn Schwartz
    Diabetes and Glandular Disease Research Associates, San Antonio, Texas 78229 4801, USA
    Diabetes Technol Ther 10:351-7. 2008
  7. doi request reprint The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Clinic of San Antonio, San Antonio, Texas 78229, USA
    Metab Syndr Relat Disord 8:179-88. 2010
  8. doi request reprint Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus
    Sherwyn L Schwartz
    Cetero Research, 5107 Medical Drive, San Antonio, TX 78229, USA
    Diabetes Technol Ther 13:1219-27. 2011
  9. doi request reprint Humalog(®) KwikPen™: an insulin-injecting pen designed for ease of use
    Sherwyn L Schwartz
    DGD Research, 5107 Medical Drive, San Antonio, TX 78229, USA
    Expert Rev Med Devices 7:735-43. 2010
  10. doi request reprint Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
    Clin Ther 30:858-67. 2008

Collaborators

Detail Information

Publications28

  1. ncbi request reprint A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus
    Sherwyn Schwartz
    Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
    Clin Ther 28:1649-57. 2006
    ....
  2. pmc Correct use of a new reusable insulin injection pen by patients with diabetes: a design validation study
    Sherwyn Schwartz
    Diabetes and Glandular Disease Research Associates, San Antonio, Texas 78229, USA
    J Diabetes Sci Technol 4:1229-35. 2010
    ..The objective of this study was to demonstrate that individuals with diabetes could use the ClikSTAR pen correctly...
  3. doi request reprint Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial
    Sherwyn Schwartz
    Cetero Research, San Antonio, TX 78229, USA
    Curr Med Res Opin 27:151-62. 2011
    ..This phase III, randomized-withdrawal, placebo-controlled trial evaluated the safety and efficacy of tapentadol extended release (ER) for relieving painful DPN...
  4. doi request reprint Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Clinic, 5107 Medical Drive, San Antonio, TX 78229, USA
    Ann Med 44:157-69. 2012
    ..On the basis of this clinical profile, saxagliptin is an attractive option for initial and add-on therapy for T2DM patients with inadequate glycemic control...
  5. ncbi request reprint A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus
    Sherwyn Schwartz
    Diabetes and Glandular Disease Research Associates, 5107 Medical Drive, San Antonio, TX 78229, USA
    Clin Ther 26:1663-78. 2004
    ..Optimal needle length for subcutaneous insulin injection may differ for obese and nonobese patients, which could affect management of diabetes mellitus (DM)...
  6. doi request reprint Validation of the SoloSTAR insulin pen
    Sherwyn Schwartz
    Diabetes and Glandular Disease Research Associates, San Antonio, Texas 78229 4801, USA
    Diabetes Technol Ther 10:351-7. 2008
    ..This study was designed to validate the use of SoloSTAR (sanofi-aventis Deutschland GmbH, Frankfurt, Germany), a new disposable pen developed for use with insulin glargine by patients with type 1 or type 2 diabetes...
  7. doi request reprint The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Clinic of San Antonio, San Antonio, Texas 78229, USA
    Metab Syndr Relat Disord 8:179-88. 2010
    ..This study evaluated the effect of colesevelam hydrochloride on insulin sensitivity, potential binding to glucose, and chronic effect(s) on fasting and postprandial glucose and insulin in patients with type 2 diabetes mellitus...
  8. doi request reprint Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus
    Sherwyn L Schwartz
    Cetero Research, 5107 Medical Drive, San Antonio, TX 78229, USA
    Diabetes Technol Ther 13:1219-27. 2011
    ..Inhibition of SGLT2 represents an innovative approach for plasma glucose control in type 2 diabetes mellitus (T2DM) by blocking glucose reabsorption and enhancing glucose loss in the urine...
  9. doi request reprint Humalog(®) KwikPen™: an insulin-injecting pen designed for ease of use
    Sherwyn L Schwartz
    DGD Research, 5107 Medical Drive, San Antonio, TX 78229, USA
    Expert Rev Med Devices 7:735-43. 2010
    ..Together with an engineering study demonstrating smoother injections and reduced dosing error versus a comparator pen, recent evidence demonstrates the Humalog KwikPen device is an accurate, easy-to-use, patient-preferred insulin pen...
  10. doi request reprint Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
    Clin Ther 30:858-67. 2008
    ..The aim of this study was to examine the glucose-lowering effect of exenatide over 24 hours in patients with type 2 diabetes with inadequate glycemic control using metformin, with or without a thiazolidinedione (TZD)...
  11. doi request reprint Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Clinic, San Antonio, Texas, USA
    Clin Ther 30:1081-8. 2008
    ..Elevated levels of cortisol have been implicated in the development of type 2 diabetes mellitus and the metabolic syndrome. Modulation of cortisol levels and activity may be useful in the treatment of type 2 diabetes and its comorbidities...
  12. ncbi request reprint Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis
    Sherwyn Schwartz
    Diabetes and Glandular Disease Clinic, San Antonio, Texas 78229, USA
    Diabetes Care 26:2238-43. 2003
    ..0%) were randomly assigned to treatment with either a third oral medication or an insulin 70/30 mix b.i.d. plus metformin for a comparison of efficacy, safety, and cost...
  13. ncbi request reprint Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes
    Sherwyn Schwartz
    Diabetes and Glandular Disease Research Associates, San Antonio, Texas, USA
    Diabetes Care 29:759-64. 2006
    ..The purpose of this study was to determine the efficacy and safety of a novel extended-release metformin in patients with type 2 diabetes...
  14. ncbi request reprint The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study
    Jerome S Fischer
    Diabetes and Glandular Disease Clinic, San Antonio, TX 78229, USA
    Curr Med Res Opin 20:1703-10. 2004
    ..The objective of this study was to evaluate the effectiveness of insulin glargine over a 12-month period in a clinical practice setting, and measure its effects on HRQOL in a subset of patients...
  15. ncbi request reprint Preference and resource utilization in elderly patients: InnoLet versus vial/syringe
    John Shelmet
    Diabetes and Glandular Disease Clinic, 5107 Medical Drive, San Antonio, TX 78229, USA
    Diabetes Res Clin Pract 63:27-35. 2004
    ..001). A majority of patients (82%) indicated a preference for the InnoLet device (P<0.001)...
  16. ncbi request reprint Diabetes and dyslipidaemia
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Clinic, San Antonio, TX 78229 4801, USA
    Diabetes Obes Metab 8:355-64. 2006
    ..3 mmol/l). Many diabetic patients may need oral hypoglycaemic agents or insulin to achieve adequate glycaemic control. Intensive insulin therapy can provide tight glycaemic control and reduce elevated triglyceride levels...
  17. ncbi request reprint Metformin extended release for the treatment of type 2 diabetes mellitus
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Clinic, San Antonio, TX 78229, USA
    Expert Opin Pharmacother 7:803-9. 2006
    ..Metformin ER was well tolerated at doses of 1500 or 2000 mg/day, with no increase in the frequency or severity of adverse events at the higher dose...
  18. ncbi request reprint Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study
    Christian Weyer
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Diabetes Care 26:3074-9. 2003
    ....
  19. ncbi request reprint Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial
    Satish Garg
    Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 1775 N Ursula St, A140, Aurora, Colorado 80010, USA
    Diabetes Care 29:44-50. 2006
    ..In this study we evaluated the accuracy, safety, and clinical effectiveness of a continuous glucose-sensing device...
  20. ncbi request reprint Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study
    David G Maggs
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Diabetes Metab Res Rev 20:55-60. 2004
    ..To assess the postprandial glucose-lowering effect of the human amylin analog pramlintide when given with insulin lispro in subjects with type 2 diabetes, with an emphasis on the optimal dose timing relative to meals...
  21. ncbi request reprint Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes
    Satish K Garg
    Department of Medicine and Pediatrics, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Diabetes Care 27:734-8. 2004
    ..The capability of emerging glucose sensor technology to continuously monitor glucose levels may provide ways to achieve glycemic targets while reducing hypoglycemia...
  22. ncbi request reprint Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, Georgia, USA
    Diabetes Technol Ther 6:105-13. 2004
    ....
  23. ncbi request reprint Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values
    Bruce W Bode
    Atlanta Diabetes Associates, Georgia, USA
    Diabetes Care 28:2361-6. 2005
    ....
  24. ncbi request reprint Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes
    Berrin Ergun-Longmire
    Division of Pediatric Endocrinology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
    Ann N Y Acad Sci 1029:260-77. 2004
    ..If confirmed, these findings suggest that diabetic patients over age 20 years with ICA evidence of late-onset immune-mediated diabetes should be considered for oral insulin at 1 mg/day to better retain endogenous insulin secretion...
  25. ncbi request reprint Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study
    Andrew Lewin
    National Research Institute, Los Angeles, CA, USA
    Clin Ther 29:844-55. 2007
    ..Combination treatment with metformin and sulfonylurea in patients who failed monotherapy has been reported to be effective in maintaining glycemic control...
  26. ncbi request reprint Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
    Yan ling He
    Novartis Institutes for BioMedical Research, Inc, Cambridge, Massachusetts 02139 3584, USA
    Clin Pharmacokinet 46:577-88. 2007
    ..Vildagliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor currently under development for the treatment of type 2 diabetes mellitus...
  27. ncbi request reprint Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria
    Hiddo Lambers Heerspink
    Department of Clinical Pharmacology University Medical Center Groningen, University of Groningen, A Deusinglaan, 19713 AV Groningen, The Netherlands
    Nephrol Dial Transplant 23:1946-54. 2008
    ..We have conducted a multi-center randomized double-blind pilot study in order to determine the effect of 6 months' therapy with sulodexide on urinary albumin excretion and to address logistical issues for a full-scale trial...
  28. ncbi request reprint A continuous glucose sensor based on wired enzyme technology -- results from a 3-day trial in patients with type 1 diabetes
    Ben Feldman
    TheraSense, Inc, Alameda, California 94502, USA
    Diabetes Technol Ther 5:769-79. 2003
    ..Choice of the site of the implanted sensor (upper arm vs. abdomen) or the capillary blood calibration site (arm vs. finger) did not affect system accuracy...